Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: An in silico analysis

Dousti, Fatemeh; Shahrisa, Arman; Ansari, Hossein; Hajjari, Mohammadreza; Birgani, Yaser Tahmasebi; Mohammadi-Asl, Javad; Birgani, Maryam Tahmasebi

doi:10.1016/j.prp.2018.08.006

Cited by 13 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer research and recent studies implicated that various lncRNAs are dysregulated in human malignancies. Aberrant expression of lncRNA is associated with the DLBCL patient's clinical characteristics and poor prognosis and can be applied to serve as a therapeutic target [16][17][18]. LncRNA HULC has been reported to play a crucial role in tumor carcinogenesis and progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway

Gao

2020

Bioscience Reports

View full text Add to dashboard Cite

Background: Diffuse large B-cell lymphoma (DLBCL) is considered the most common aggressive subtype of lymphoma. A number of DLBCL patients fail to achieve a response to currently available therapies or develop resistance. β-Elemene is derived from herb Curcuma wenyujin, and exhibits anti-tumor activity in both solid and non-solid tumors through modulating several molecular signaling pathways. We aimed to explore the role of β-elemene in DLBCL treatment and elucidate the involved mechanism. Materials and methods: Cell viability, apoptosis and expressions of related proteins were assessed and in vivo study were performed to determine the tumor suppressive effect of β-elemene and explore the molecular mechanisms. Results: β-Elemene significantly suppressed the viability of DLBCL cells, and β-elemene down-regulated the lncRNA HULC expression and regulated key pro-apoptotic and anti-apoptotic proteins to induce significant apoptosis of DLBCL cells. HULC overexpression could decrease the β-elemene induced apoptosis, while HULC knockdown increased the apoptosis in DLBCL cells. In vivo study further confirmed that β-elemene could suppress the growth of DLBCL xenograft and regulate the HULC expression and the critical proteins of the apoptotic pathway. Conclusion: β-Elemene performs as a tumor suppressor and modulator of HULC-mediated apoptotic pathway in DLBCL and will be an alternative candidate for clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Long non-coding RNA (lncRNA) that is greater than 200 nucleotides has been reported to be associated with the development of lymphoma, including DLBCL [16][17][18]. Aberrant expression of lncRNA is associated with DLBCL occurrence and development.…”

Section: Introductionmentioning

confidence: 99%

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway

Gao

2020

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…Lastly, an in silico analysis analyzed 189 lncRNAs, extracted from the HUGO Gene Nomenclature Committee (HGNC), and demonstrated that 83% of DLBCL patients showed dysregulation for the studied lncRNAs. Growth arrest-specific 5 (GAS5), highly up-regulated in liver cancer (HULC), miR-17-92a-1 cluster host gene (MIR17HG), and prostate cancer antigen 3 (PCA3) were the transcripts with the highest dysregulation score [128]. The potential of lncRNA expression profiling as biomarker in DLBCL was underlined by a meta-analysis conducted by Xu et al [129].…”

Section: Long Non-coding Rnamentioning

confidence: 99%

Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review

2021

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common histological subtype of non-Hodgkin’s lymphomas (NHL). DLBCL is an aggressive malignancy that displays a great heterogeneity in terms of morphology, genetics and biological behavior. While a sustained complete remission is obtained in the majority of patients with standard immunochemotherapy, patients with refractory of relapsed disease after first-line treatment have a poor prognosis. This patient group represents an important unmet need in lymphoma treatment. In recent years, improved understanding of the underlying molecular pathogenesis had led to new classification and prognostication tools, including the development of cell-free biomarkers in liquid biopsies. Although the majority of studies have focused on the use of cell-free fragments of DNA (cfDNA), there has been an increased interest in circulating-free coding and non-coding RNA, including messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA) and circular RNA (circRNA), as well as RNA encapsulated in extracellular vesicles or tumor-educated platelets (TEPs). We performed a systematic search in PubMed to identify articles that evaluated circulating RNA as diagnostic, subtype, treatment response or prognostic biomarkers in a human DLBCL population. A total of 35 articles met the inclusion criteria. The aim of this systematic review is to present the current understanding of circulating RNA molecules as biomarker in DLBCL and to discuss their future potential.

show abstract

“…105 In an in silico study, among 189 candidate lncRNAs, growth arrestspecific 5 (GAS5), miR-17-92a-1 cluster host gene (MIR17HG), highly upregulated in liver cancer (HULC), and prostate cancer antigen 3 (PCA3) were found to be highly altered in DLBCL patients, and abnormal expression of GAS5 was most commonly detected. 106…”

Section: Expression Of Lncrnas In Dlbclmentioning

confidence: 99%

<p>Non-Coding RNAs in Diffuse Large B-Cell Lymphoma</p>

Shi

Ding

et al. 2020

OTT

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide. The molecular mechanisms underlying DLBCL have not been fully elucidated, and approximately 40% of patients who undergo standard chemoimmunotherapy still present with primary refractory disease or relapse. Non-coding RNAs (ncRNAs), a group of biomolecules functioning at the RNA level, are increasingly recognized as vital components of molecular biology. With the development of RNA-sequencing (RNA-Seq) technology, accumulating evidence shows that ncRNAs are important mediators of diverse biological processes such as cell proliferation, differentiation, and apoptosis. They are also considered promising biomarkers and better candidates than proteins and genes for the early recognition of disease onset, as they are associated with relative stability, specificity, and reproducibility. In this review, we provide the first comprehensive description of the current knowledge regarding three groups of ncRNAs-microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs)-focusing on their characteristics, molecular functions, as well as diagnostic and therapeutic potential in DLBCL. This review provides an exhaustive account for researchers to explore novel biomarkers for the diagnosis and prognosis of DLBCL and therapeutic targets.

show abstract

Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: An in silico analysis

Cited by 13 publications

References 31 publications

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway

Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review

<p>Non-Coding RNAs in Diffuse Large B-Cell Lymphoma</p>

Contact Info

Product

Resources

About